Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Vicore to Present at Upcoming Investor Conferences

Vicore Pharma Holding

Stockholm, August 28, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following conferences:

  • Cantor Global Healthcare Conference 2025
    Location: New York, USA
    Format: Fireside chat and 1x1 meetings
    Presentation Date and Time: Wednesday, September 3 at 1:00 PM ET
    Webcast: Registration
    Participants: Ahmed Mousa, CEO
  • Wells Fargo Healthcare Conference 2025
    Location: Boston, USA
    Format: Fireside chat and 1x1 meetings
    Presentation Date and Time: Friday, September 5 at 12:00 PM ET
    Webcast: Registration
    Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR
  • Morgan Stanley Global Healthcare Conference 2025
    Location: New York, USA
    Format: Fireside chat and 1x1 meetings
    Presentation Date and Time: Monday, September 8 at 10:00 AM ET
    Webcast: Registration
    Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR


The company’s management team will also be available for meetings at the conferences. Interested parties may access the webcast replay on the Events & Presentations page of Vicore’s website for 90 days following the conclusion of the event.

For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com  
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.

The company’s shares are listed on Nasdaq Stockholm’s main market (VICO). www.vicorepharma.com

Attachments
Vicore to Present at Upcoming Investor Conferences

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.